सिस्टमिक कीमोथेरेपी द्वारा आवश्यक IgM रिडक्शन प्राप्त न होने पर हाइपरविस्कोसिटी सिंड्रोम

References

DOI: 10.1182/blood-2018-06-846816

• For patients who have hyperviscosity, an indication for therapy, and no symptoms, rapid-acting systemic chemotherapy can reduce the serum viscosity and obviate the need for plasma exchange.
• The standard of care for managing hyperviscosity of the plasma is therapeutic apheresis, and guidelines on the use of apheresis have been previously published, and hyperviscosity is considered category A evidence for plasma exchange.
• Plasma exchange will decrease the plasma viscosity anywhere from 30% to 50% in a single session that exchanges 1 volume of the patient's plasma.